Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification

Oncology

Volumn 68, Issue 1, 2005, Pages 79-86

  Yu, Yun ^a   Chen, Sheng ^a   Wang, Li Shun ^a   Chen, Wen Li ^a   Guo, Wei Jian ^b   Yan, Hua ^a   Zhang, Wei Hua ^d   Peng, Cheng Hong ^a   Zhang, Sheng Dao ^a   Li, Hong Wei ^a   Chen, Guo Qiang ^a,c  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

Biomarkers; Mass spectrum; Pancreatic cancer; Serum biomarkers; Surface enhanced laser desorption ionization

Indexed keywords

PROTEIN; TUMOR MARKER;

ADULT; AGED; ALGORITHM; ARTICLE; ARTIFICIAL INTELLIGENCE; BLOOD ANALYSIS; BLOOD CHEMISTRY; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DIAGNOSTIC ACCURACY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN MICROARRAY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; BLOOD; DECISION TREE; MASS SPECTROMETRY; MIDDLE AGED; PANCREAS TUMOR; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; DECISION TREES; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 20944441736     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084824     Document Type: Article

References (25)

1. DiMagno EP, Reber HA, Tempero MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999;117:1464-1484.
2. Li D, Xie K, Wolff R, Abbruzzese JL: Pancreatic cancer. Lancet 2004;363:1049-1057.
3. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ, American Cancer Society: Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
4. Rosty C, Goggins M: Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002;16:37-52.
5. Kalra MK, Maher MM, Mueller PR, Saini S: State-of-the-art imaging of pancreatic neoplasms. Br J Radiol 2003;76:857-865.
6. Goggins M, Canto M, Hruban R: Can we screen high-risk individuals to detect early pancreatic carcinoma? J Surg Oncol 2000;74:243-248.
7. Hanash SM: Global profiling of gene expression in cancer using genomics and proteomics. Curr Opin Mol Ther 2001;3:538-545.
8. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA: Clinical proteomics: Translating benchside promise into bedside reality. Nat Rev Drug Discov 2002;1:683-695.
9. Verma M, Wright GL Jr, Hanash SM, Gopal-Srivastava R, Srivastava S: Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann NY Acad Sci 2001;945:103-115.
10. Merchant M, Weinberger SR: Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000;21:1164-1177.
11. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-577.
12. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R: Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003;100:12343-12348.
13. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA: Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-1578.
14. Banez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam BL, McLeod DG, Moul JW, Srivastava S: Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003;170:442-446.
15. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL Jr: Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48:1835-1843.
16. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-3614.
17. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-1304.
18. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW: Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 2003;3:2310-2316.
19. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright GL Jr: Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-1502.
20. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M: Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-868.
21. Anderson NL, Anderson NG: The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-867.
22. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF 3rd, Liotta LA: Biomarker amplification by serum carrier protein binding. Dis Markers 2003;19:1-10.
23. Petricoin EF, Liotta LA: SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004;15:24-30.
24. Petricoin E 3rd, Liotta LA: Counterpoint: The vision for a new diagnostic paradigm. Clin Chem 2003;49:1276-1278.
25. Diamandis EP: Point: Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272-1275.